Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Apr 14;29(5):1103–1112. doi: 10.1038/s41591-023-02321-8

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Extended Data Fig. 4 — Efficacy evaluable population: Primary and expansion cohorts in all except low grade glioma and multiple myeloma which are primary analysis cohorts. ATC: Among 36 patients, 24 (67%) patients died, 12 (33%) patients were censored due to end of follow-up. BTC: Among 43 patients, 34 (79%) patients died, nine (21%) patients were censored due to end of follow-up. ASI: All three patients died during the study LGG: Among 13 patients (in the primary analysis cohort), four (31%) patients died, nine (69%) patients were censored due to end of follow-up. HGG: Among 45 patients, 28 (62%) patients died, 17 (38%) patients were censored due to end of follow-up. HCL: Among 55 patients, eight (15%) patients died, 47 (85%) patients were censored due to end of follow-up. MM: Among 10 patients, nine (90%) patients died, one patient was censored due to end of follow up. ASI, adenocarcinoma of small intestine; ATC, anaplastic thyroid cancer; BTC, biliary tract cancer; G, grade; HCL, hairy cell leukemia; HGG, high (WHO G3/G4) grade glioma; LGG, low (WHO G1/G2) grade glioma; MM, multiple myeloma; WHO, World Health Organization.